Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2019 09:25 ET | Source: Rezolute, Inc.

Rezolute Appoints Nektar Therapeutics COO & CFO to Its Board of Directors

REDWOOD CITY, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a biopharmaceutical company specializing in the development of innovative drug...
October 11, 2019 16:24 ET | Source: Rezolute, Inc.

Rezolute Management to Present at 2019 BIO Investor Forum Conference

REDWOOD CITY, Calif., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2019 BIO Investor Forum...
August 05, 2019 09:25 ET | Source: Rezolute, Inc.

Rezolute Management to Present at 2019 Canaccord Genuity Growth Conference

REDWOOD CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), today announced that senior management will present at the 2019 Canaccord Genuity...
July 24, 2019 09:25 ET | Source: Rezolute, Inc.

Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option

REDWOOD CITY, Calif., July 24, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of transformative...
January 07, 2019 08:39 ET | Source: Rezolute, Inc.

Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million

REDWOOD CITY, Calif., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
May 16, 2018 08:00 ET | Source: Rezolute, Inc.

Rezolute Announces Appointment of Keith Vendola as Chief Financial Officer

LOUISVILLE, Colo., May 16, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
April 09, 2018 08:00 ET | Source: Rezolute, Inc.

Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development

LOUISVILLE, Colo., April 09, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
April 04, 2018 08:00 ET | Source: Rezolute, Inc.

Rezolute Announces Appointment of Hoyoung Huh, M.D., Ph.D. as Vice Chairman of its Board of Directors

LOUISVILLE, Colo., April 04, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
April 03, 2018 13:26 ET | Source: Rezolute, Inc.

Rezolute, Inc. Announces Close of Convertible Note Financing

LOUISVILLE, Colo., April 03, 2018 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...
December 26, 2017 11:41 ET | Source: Rezolute, Inc.

UPDATE - Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC

LOUISVILLE, Colo., Dec. 26, 2017 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:RZLT), a clinical stage biopharmaceutical company specializing in the development of...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right